NatInLab

What makes us unique?

We are an ambitious pharmaceutical start-up at the forefront of innovation, founded by a multidisciplinary scientist with a passion for advancing human health. Leveraging our cutting-edge de novo drug design technology, we specialize in crafting next-generation inhibitor therapeutics targeting medically significant proteases. By seamlessly integrating computational science, chemistry, systems and molecular biology, we aim to tackle unmet medical needs and transform the treatment landscape for challenging neurodegenerative diseases.

Our claim

Many pathological conditions arise from the disruption of proteolytic pathways, often caused by the absence or imbalance of critical regulatory compounds.

Our goal

We discover the regulatory mechanisms and based on those discoveries, we develop new medicines.

Our approach

We focus on deciphering the natural mechanisms of cellular self-regulation within key proteolytic pathways. By understanding these intricate processes, we aim to design targeted therapeutics that restore balance and address the root causes of pathological conditions.

Our Technology (AI-Powered Medicinal Chemistry)

We leverage Artificial Intelligence to first deeply understand the molecular intricacies of proteolytic pathways and their regulatory mechanisms. Building on this foundation, our technology enables the creation of precise, next-generation therapeutic compounds, accelerating the journey from discovery to impactful solutions.

R&D

Neurodegenerative diseases

ALZHEIMER'S DRUG DEVELOPMENT PROGRAMME

We have developed an innovative drug design technology specifically targeting proteases, which we are now applying to a critical target in Alzheimer's pathology.

Our decision is driven by our commitment to addressing urgent societal health challenges such as Alzheimer's disease.

The proof-of-concept results are highly promising, and we are confident that our technology holds great potential to drive meaningful progress in treatment options for neurodegenerative diseases.

Team

Ewelina Weglarz-Tomczak, Ph.D.

Founder, CEO & CSO
Ph.D. in Biochemistry
M.Sc. in Medicinal Chemistry

Katarzyna Abrantes Mendes

Operations & Marketing
M.Sc. in Sociology, Communication and Market Studies
M.Sc. in Management

Zuzanna Senkowska

Research & Development
M.Sc. in Medicine Biotechnology (ongoing)
B.Sc. in Medicine Biotechnology

Larissa McGinn

Research & Development
M.Sc. in Cognitive Neurobiology and Clinical Neurophysiology (ongoing)
B.Sc. in Biology, Behavior and Neuroscience

Caroline van Wingerde

Research & Development
M.Sc. in Molecular Neuroscience (ongoing)
B.Sc. in Biopharmaceutical Science

Stacy Maciel

Research & Development
M.Sc. in Biomedical Science (ongoing)
B.Sc. in Cognitive and Behavioral Neuroscience

Advisory Board

Prof. Anna Maria Colangelo

Advisor in Neurobiology
University of Milano-Bicocca

Prof. Marten Smidt

Advisor in Neuroscience
University of Amsterdam

Jakub Tomczak, Ph.D.

Principal Scientist, AI
Eindhoven University of Technology

Marc Roelofs Ph.D.

Investment Manager
UvA AMC HvA Ventures Holding BV

Investment

Investment & Business Collaboration

We are currently raising funds in our pre-seed round to accelerate research and strengthen our multidisciplinary team. We believe in making safe Alzheimer's drugs a reality. Join us on this journey and make a meaningful impact in people’ lives. Feel free to contact us for details about our progress, financials, and how your support can play a pivotal role in our success!

Contact

Our Address

Science Park, Amsterdam

Email Us

contact@natinlab.com

reach out